These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

119 related items for PubMed ID: 1928076

  • 1. Erythropoietin 1991--an overview.
    Eschbach JW.
    Am J Kidney Dis; 1991 Oct; 18(4 Suppl 1):3-9. PubMed ID: 1928076
    [Abstract] [Full Text] [Related]

  • 2. The effect of i.v. iron alone or in combination with low-dose erythropoietin in the rapid correction of anemia of chronic renal failure in the predialysis period.
    Silverberg DS, Blum M, Agbaria Z, Deutsch V, Irony M, Schwartz D, Baruch R, Yachnin T, Steinbruch S, Iaina A.
    Clin Nephrol; 2001 Mar; 55(3):212-9. PubMed ID: 11316241
    [Abstract] [Full Text] [Related]

  • 3. Epoetin: human recombinant erythropoietin.
    Flaharty KK, Grimm AM, Vlasses PH.
    Clin Pharm; 1989 Nov; 8(11):769-82. PubMed ID: 2680241
    [Abstract] [Full Text] [Related]

  • 4. Clinical efficacy of recombinant human erythropoietin in hemodialysis patients.
    Mohini R.
    Semin Nephrol; 1989 Mar; 9(1 Suppl 1):16-21. PubMed ID: 2648516
    [Abstract] [Full Text] [Related]

  • 5. Treatment of the anemia of progressive renal failure with recombinant human erythropoietin.
    Eschbach JW, Kelly MR, Haley NR, Abels RI, Adamson JW.
    N Engl J Med; 1989 Jul 20; 321(3):158-63. PubMed ID: 2747747
    [Abstract] [Full Text] [Related]

  • 6. Iron-replete hemodialysis patients do not require higher EPO dosages when converting from subcutaneous to intravenous administration: results of the Italian Study on Erythropoietin Converting (ISEC).
    Pizzarelli F, David S, Sala P, Icardi A, Casani A.
    Am J Kidney Dis; 2006 Jun 20; 47(6):1027-35. PubMed ID: 16731298
    [Abstract] [Full Text] [Related]

  • 7. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial.
    Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW.
    N Engl J Med; 1987 Jan 08; 316(2):73-8. PubMed ID: 3537801
    [Abstract] [Full Text] [Related]

  • 8. Correction of anaemia in haemodialysis patients with recombinant human erythropoietin.
    Boran M, Dalva I, Yazicioğlu A, Akbay E, Cetin S.
    Int Urol Nephrol; 1993 Jan 08; 25(2):197-203. PubMed ID: 8365853
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease.
    Besarab A, Salifu MO, Lunde NM, Bansal V, Fishbane S, Dougherty FC, Beyer U, Ba16285 Study Investigators.
    Clin Ther; 2007 Apr 08; 29(4):626-39. PubMed ID: 17617286
    [Abstract] [Full Text] [Related]

  • 10. [Guidelines for the treatment of anemia in chronic renal failure].
    Triolo G, Italian Society of Nephrology.
    G Ital Nefrol; 2003 Apr 08; 20 Suppl 24():S61-82. PubMed ID: 14666504
    [Abstract] [Full Text] [Related]

  • 11. Clinical administration of epoetin alfa recombinant.
    Taylor BA, Weinstein SM.
    J Intraven Nurs; 1992 Apr 08; 15(2):78-82. PubMed ID: 1564606
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Erythropoietin therapy in patients with chronic renal failure.
    Pinevich AJ, Petersen J.
    West J Med; 1992 Aug 08; 157(2):154-7. PubMed ID: 1441466
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Who should receive recombinant human erythropoietin?
    Van Stone JC.
    Semin Nephrol; 1989 Mar 08; 9(1 Suppl 2):3-7. PubMed ID: 2669084
    [Abstract] [Full Text] [Related]

  • 16. Epoetin alfa for the treatment of the anemia of multiple myeloma. A prospective, randomized, placebo-controlled, double-blind trial.
    Garton JP, Gertz MA, Witzig TE, Greipp PR, Lust JA, Schroeder G, Kyle RA.
    Arch Intern Med; 1995 Oct 23; 155(19):2069-74. PubMed ID: 7575066
    [Abstract] [Full Text] [Related]

  • 17. Management of iron deficiency in renal anemia: guidelines for the optimal therapeutic approach in erythropoietin-treated patients.
    Drüeke TB, Bárány P, Cazzola M, Eschbach JW, Grützmacher P, Kaltwasser JP, Macdougall IC, Pippard MJ, Shaldon S, van Wyck D.
    Clin Nephrol; 1997 Jul 23; 48(1):1-8. PubMed ID: 9247771
    [Abstract] [Full Text] [Related]

  • 18. Iron deficiency in patients with dialysis-associated anemia during erythropoietin replacement therapy: strategies for assessment and management.
    Van Wyck DB.
    Semin Nephrol; 1989 Mar 23; 9(1 Suppl 2):21-4. PubMed ID: 2669082
    [Abstract] [Full Text] [Related]

  • 19. Monitoring considerations in recombinant human erythropoietin therapy.
    Ogden DA.
    Semin Nephrol; 1989 Mar 23; 9(1 Suppl 2):12-5. PubMed ID: 2669080
    [Abstract] [Full Text] [Related]

  • 20. Erythropoietin use in peritoneal dialysis patients.
    Zimmerman SW, Johnson CA.
    Am J Kidney Dis; 1991 Oct 23; 18(4 Suppl 1):38-41. PubMed ID: 1928078
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.